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Abstract
In this paper we consider two-stage adaptive dose-response study de-
signs, where the study design is changed at an interim analysis based on
the information collected so far. In a simulation study, two approaches will
be compared for these type of designs; (i) updating the study design by
calculating the maximum likelihood estimate for the dose-response model
parameters and then calculating the design for the second stage that is
locally optimal for this estimate, and (ii) using the complete posterior dis-
tribution of the model parameter at interim to calculate a Bayesian optimal
design (i.e. taking into account parameter uncertainty). In particular, for
an early interim analysis respecting parameter uncertainty seems more ad-
equate, on the other hand for a Bayesian approach dependency on the prior
is expected and an adequately thought-through prior is required. A compu-
tationally efficient method is proposed for calculating the Bayesian design
at interim based on approximating the full posterior sample using k-means
clustering. The sigmoid Emax dose-response model and the D-optimality
criterion will be used in this paper.
Keywords: adaptive dose-finding, Bayesian optimal design, D-optimality,
k-means clustering, Hill equation, sigmoid Emax
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1 Introduction
In the past few years there has been substantial interest in adaptive dose-finding
studies, see for example, the white papers of the PhRMA Working Group for
Adaptive Dose-Ranging Designs (Bornkamp et al., 2007; Dragalin et al., 2010).
Other references include Grieve and Krams (2005); Dragalin et al. (2007); Miller
et al. (2007); Berry et al. (2010); Bornkamp et al. (2011); Jones et al. (2011)
among many others. As fixed designs are more often used in clinical practice,
one obvious question is to characterize situations when an adaptive design will
outperform a non-adaptive design from a statistical efficiency perspective. In
practice, of course also non-statistical (or alternative statistical) considerations
will play a role at the trial design stage, when one decides for or against using
an adaptive design, but we will focus on statistical estimation efficiency in this
paper.
To that end, Dette et al. (2013) investigated two-stage designs, where an
interim analysis is performed and the maximum likelihood (ML) estimate of the
model parameters is used to calculate a locally optimal design for the second
stage of the trial. Based on analytical approximations they identified key factors,
when adaptive designs are beneficial, including signal to noise ratio (the larger the
better for adaptive designs), timing of the interim analysis (if the interim estimate
is too early the interim estimate might be too noisy to produce a good design,
whereas if the interim analysis is too late there might be not enough patients left
to allocate into the trial for the calculated optimal design), and adequacy of the
starting design (if an adequate starting design is used, there might not be much
to improve).
A problem of the ML approach discussed in Dette et al. (2013) is that the
study design is optimized based on the ML point estimate at the interim. By using
only a point estimate, the uncertainty in the parameter estimate is ignored and
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potentially plausible parameter values discarded, ultimately leading to designs
optimized for the “wrong” parameter values. Uncertainty can be accounted for
at the interim analysis by adopting a Bayesian approach with prior distributions
for the model parameters specified at the beginning of the trial and the posterior
distribution based on the first stage data being utilized at the interim analysis to
update the study design.
The primary aim of this work is to investigate whether there are any gains to
be made by accounting for parameter uncertainty at the interim by using Bayesian
methods or whether ML updating of the optimal design is preferable. As ana-
lytical considerations such as those discussed in Dette et al. (2013) are infeasible
for the Bayesian designs considered here, we conducted a large-scale simulation
study in the realistically relevant settings of the PhRMA working group. As we
concentrate on parameter uncertainty in this paper and not model uncertainty, we
only use the sigmoid Emax model (MacDougall, 2006): It is commonly used for
modeling the dose-response relationship and its main assumption is monotonicity
which is a desirable feature for modeling many clinical trial dose-response curves
(Kirby et al., 2011). In addition the sigmoid Emax model has been found to
give a good approximation to a number of other possible dose-response models as
well (Thomas, 2006). The design criterion used will be D-optimality. The type
of adaptation under consideration involves changing the randomisation ratios to
existing dose-levels based on efficacy.
2 Methodology
2.1 Statistical model
Let Y be a clinical outcome observed at a dose level x ∈ [0, D] where 0 and
D are the placebo and maximum dose, respectively. A parallel group design is
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used where several active dose levels plus a placebo are considered, with patients
being randomized to one of the treatments. There are q discrete doses avail-
able, with q being a fixed number and the grid of available doses being denoted
x = (x1, . . . , xq).
Consider the following regression model
Yij = η(xi,θ) + ij, ij ∼ N(0, σ2) (1)
where Yij denotes the response of patient j at dose xi (i = 1, . . . , q,j = 1, . . . , ni)
and ij is the residual error, which is assumed to be independent and normally
distributed with common variance σ2. The true, but unknown, r-parameter dose-
response model is denoted by η(xi,θ) with parameter vector θ = (θ1, . . . , θr). The
total sample size is
∑q
i=1 ni = N where ni denotes the number of patients assigned
to dose xi.
2.1.1 Sigmoid Emax model
The four parameter sigmoid Emax model is defined as
η(xi,θ) = θ1 + θ2
xθ4i
θθ43 + x
θ4
i
(2)
where θ1 denotes the placebo effect, θ2 is the asymptotic maximum treatment
effect (often called Emax), θ3 is the dose that gives half of the maximum treatment
effect (often called ED50), and θ4 is the so-called Hill parameter that determines
the steepness of the curve.
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The gradient of the sigmoid Emax model, g(x,θ), is given as
g(x,θ) =
(
1,
1
1 + (θ3/x)θ4
,
−θ4θ2θ(θ4−1)3
xθ4(1 + (θ3/x)θ4)2
,
−θ2 log(θ3/x)(θ3/x)θ4
(1 + (θ3/x)θ4)2
)
(3)
Here there are discrete dose levels and so the Fisher information matrix for
the statistical model given in (1) for a sigmoid Emax model is defined as
M (x,w,θ) =
q∑
i=1
wig(xi,θ)
Tg(xi,θ) (4)
where wi = ni/N is the proportion of patients allocated to dose xi and w =
(w1, . . . , wq). If a dose from the grid of available doses x1, . . . , xq is not allocated
any patients then wi = 0. Note that the Fisher information matrix for the
nonlinear sigmoid Emax model (Equation 4) is dependent on the unknown true
parameter values θ and the experimental design ξ = (x,w).
2.2 Two-stage D-optimal design
A fixed (or non-adaptive) design is a design in which observations are taken at
pre-specified doses. In a two-stage adaptive design, the data accrued in the first
stage is used to determine the design for the second stage, as follows;
1. Stage 1: N (1) observations at starting design ξ(1).
2. Interim updating: fit the sigmoid Emax model to the first stage data and
use the obtained information about the model parameters θ to calculate
the optimal design for the second stage, ξ(2).
3. Stage 2: N (2) = N −N (1) observations based on updated design ξ(2).
Step 2 in the procedure above will be different for the ML-based updating and
the Bayesian updating. In this paper, the entire dose-response curve is of interest
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and so the D-optimal design is calculated at the interim analysis. A design
is D-optimal if it maximizes the determinant of the Fisher information matrix
or, equivalently, minimizes the generalized variance of the parameter estimates.
Such an optimal design minimizes the volume of the confidence ellipsoid of the
parameters, and minimizes the maximum predicted variance around the dose-
response curve (Atkinson et al., 2007, Ch.10,11).
2.3 Interim updating
For both types of updating the same grid of pre-specified discrete doses are avail-
able at the interim and so the weights are optimised whilst the doses remain fixed.
A continuous optimal design is calculated and then rounded to a fixed number of
patients so that the total number of patients N is achieved (Pukelsheim, 2006,
Chapter 12).
2.3.1 Maximum Likelihood updating
At the interim, the sigmoid Emax model is fitted to the data from the first stage
using the "fitMod" function from the DoseFinding R package (Bornkamp et al.,
2013) which implements nonlinear least squares regression. Bounds will be used
for the nonlinear parameters θ3 and θ4; this is a sufficient condition for existence
of the ML estimate, see Jennrich (1969). The bounds [0.001, 1.5D] for the θ3
parameter and [0.5, 10] for the θ4 will be used (here D is the maximum used
dose). Both boundaries are chosen relatively wide to allow essentially all shapes
of the underlying sigmoid Emax shape in the considered dose-range [0, D].
After the ML estimate has been calculated the estimates are then input to the
Fisher information matrix (Equation 4). The optimal design for the second stage,
ξ(2), is found by maximising the vector of weights, w, in the following expression:
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ξ(2) = arg max
w
|M(x,w, θˆ(1))| = arg max
w
det
[
q∑
i=1
wig(xi, θˆ
(1)
)Tg(xi, θˆ
(1)
)
]
(5)
This optimisation is carried out using the "optDesign" function in the DoseFind-
ing package in R, which performs a nonlinear optimization using an augmented
Lagrange method. The remaining N (2) patients are then assigned to the optimal
design, ξ(2), for the second stage.
2.3.2 Bayesian updating
The conceptual framework behind the Bayesian optimal design is the assumption
that the information of the parameters of interest and their uncertainty can be
adequately captured in the probability distribution. This probability density
averages out the parameter values and the criterion is no longer dependent on
the parameters. The Bayesian D-optimality criterion is defined in Atkinson et al.
(2007) as
ΨB(ξ) = Eθ [log |M(ξ,θ)|] =
∫
θ
log |M(ξ,θ)|p(θ)dθ (6)
where M(ξ,θ) is the Fisher information matrix and p(θ) is the density capturing
the information on θ. This type of design is more robust than a locally optimal
design in the sense that the performance will be adequate for parameter values
that have relevant probability mass, whereas for a locally optimal design one
only considers a single parameter value. In many situations p(θ) might be a prior
distribution; in this paper the distribution used in the design criterion will be
the posterior distribution p(θ|y(1)) based on the data observed in the first stage
of the trial. Note that this distribution will contain less information (e.g. it will
have a larger posterior variance) if an early interim analysis is performed. When
the posterior is calculated on a late interim the density will be more peaked. The
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“robustness” of the design criterion hence automatically adapts to the amount of
information available. The ML based approach in contrast always uses the point
estimate without acknowledging the uncertainty associated with it.
For the sample size and signal-to-noise ratio of interest in dose-finding studies
there will be a dependence on the prior distribution specified at the beginning of
the trial (Temple (2012); Bornkamp (2012)), in particular if the interim analysis
is performed early in the trial. For the purpose of generic simulations, outside a
concrete real example, it is difficult to come up with examples of prior information
one might have, so the focus in this paper will be on the situation of little prior
information. It is clear, that a fully Bayesian approach will be better than the
maximum-likelihood approach if relevant historical prior information is available,
so the situation considered in the simulations might be considered conservative
for the performance of the Bayesian approach.
The functional uniform prior distribution
One potential weakly informative prior distribution is the Jeffreys prior distribu-
tion, as for example discussed in (Gelman et al., 2003, p.63). Here one uses
p(θ) ∝ |M(x,w,θ)|1/2, (7)
where M (x,w,θ) is the Fisher information matrix defined in Equation (4). So
the Jeffreys prior depends on the Fisher information matrix, which in turn de-
pends on the observed design (x,w). However, in a two-stage trial the design at
the interim will be different to the design at study end, so that the Jeffreys prior
will be different at interim and study end, which is why the prior violates the
likelihood principle (Ghosh et al., 2006).
Functional uniform priors (Bornkamp, 2012, 2014) strive to derive a distribu-
tion that is uniformly distributed on the potential different shapes of the under-
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lying nonlinear model function. These priors are invariant with respect to param-
eterization of the model function and typically result in rather non-uniform prior
distributions on the parameter scale. When using the L2 distance at the grid of
available doses x1, . . . , xq with equal weight to define functional uniformity, one
obtains a functional uniform distribution that is essentially a modified version of
Jeffreys prior (Bornkamp, 2012). Instead of the actual observed design one uses
the x values and weights for w used in the L2 distance. Here we will use the
grid x of all doses available and equal weights w. This prior will then no longer
violate the likelihood principle (it is completely specified before trial start) and
has the clear interpretation of being uniformly distributed on the different shapes
available in the chosen distance metric. The same parameter bounds as for ML
estimation will be used for the Bayesian approach. This is the prior used in this
paper.
Numerical calculations to update Bayesian designs
Two numerically challenging tasks are involved in calculation of the updated
design at the interim analysis based on the Bayesian approach; (i) one needs to
perform the integration in Equation (6) to evaluate the design criterion once,
and (ii) one needs to optimize the design criterion with respect to the design,
requiring multiple evaluations of Equation (6) for different candidate designs.
One approach to perform the integration is to use Monte Carlo. That means
at the interim analysis JAGS will be used to create a Markov chain Monte Carlo
sample of size 10000 from the posterior distribution. The integral can then be
estimated as the corresponding arithmetic mean. So for 10000 samples from
the posterior distribution this requires calculation of 10000 evaluations of the
determinant of the Fisher information to evaluate the criterion for one design.
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This can become time consuming, in particular because evaluation of the design
criterion is embedded in the numerical optimization. In context of a simulation
study this approach would be computationally prohibitive.
A more efficient alternative to pure Monte Carlo is to use k-means clustering
to approximate the full posterior distribution for the parameters by a weighted
discrete distribution. The k-means cluster algorithm partitions n observations
into k clusters so as to minimise the within-cluster sum of squares (Wu, 2012). So
instead of using all posterior samples, each weighted equally, a weighted mean is
used, based on the identified cluster centers (and corresponding cluster weights),
so that the determinant of the Fisher information needs to be evaluated less often
for one evaluation of the design criterion. The Hartigan and Wong (1979) k-means
clustering algorithm implemented in R in the function kmeans will be used.
Theoretically for a large number of cluster centers (and a large posterior sam-
ple), the k-means approximation of the integral should be close to the correct
integral, in Appendix A we outline some heuristic mathematical arguments that
support this. In practice it is unclear how many cluster centers will provide
an adequate approximation of the integral and so a small simulation study was
conducted, where k = 10 cluster centers were used. Actual calculation of the
optimal design was performed with the "optDesign" function, where the cluster
centers were used for the model parameters and the corresponding cluster weights
specified. The cluster weights correspond to the proportion of posterior samples
associated with each of the cluster centres.
We used one of the simulation scenarios studied in the simulation study de-
scribed later to evaluate the loss of efficiency when using the k-means approx-
imation instead of the full posterior, see Appendix B for the exact simulation
scenario. The relative performance is defined as
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RelativePerformance =
ΨB(ξ
∗
km)
ΨB(ξ∗fp)
(8)
where ξ∗km is the optimal design calculated using the k-means approximation, ξ
∗
fp
is the optimal design calculated using the full posterior sample and ΨB the Bayes
design criterion from Equation (6).
Figure 1 shows one example of the distribution of efficiencies for 1000 datasets
simulated using a sigmoid Emax model with 15 observations. The sample size
was chosen to be small, as in these situations it is assumed that the posterior has
the most complex shape, and is most difficult to approximate.
Relative performance
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Figure 1: Relative performance of k-means approximation to full posterior
The k-means approximation for the full posterior is fairly good with an average
efficiency of 0.915 for this scenario. The approximation improves as the sample
size in the first stage of the trial increases with an average efficiency of 0.961 and
0.976, for sample sizes 60 and 150, respectively.
In a scenario with a total sample size of 250 the k-means approximation re-
quired on average 7.7 seconds to calculate the optimal design, compared to 124.9
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seconds for the calculation of optimal design using the full posterior distribution
(refer to Appendix B for the simulation scenario). The distributions of the run-
ning time for 100 simulations are shown in Figure 2, when using (a) the k-means
approximation and (b) the full posterior distribution. So a more than 10-fold
reduction in computing time can be achieved by using this approximation.
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(a) K-means approximation
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Figure 2: Distribution of running times for calculation of the second stage design
3 Simulations
In total, 448 different scenarios were considered in the simulations. Each scenario
correspond to a different combination of starting design, dose-response profile,
total sample size, timing of the interim analysis and type of interim updating.
The scenarios selected are similar to those conducted by the PhRMA Adaptive
Dose-Ranging Designs Working Group (Bornkamp et al., 2007). In the PhRMA
Working Group paper, a comprehensive simulation study based on a hypothetical
neuropathic pain study was conducted to evaluate existing adaptive dose-ranging
methods. The primary endpoint considered was the change from baseline at 6
weeks in a visual analog scale (VAS) of pain and this is taken to be the primary
endpoint in the following simulation study. The VAS measurements are on a
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continuous scale from 0 (no pain) to 10 (highest pain). If the VAS measurement
at the kth week is denoted by V ASk with k = 0, 1, . . . , 6 and k = 0 representing
the baseline, then the primary endpoint is defined as
y = V AS6 − V AS0 (9)
Hence, negative values of y indicate efficacy as there is a reduction in neuropathic
pain.
3.1 Starting designs
In order to investigate the impact of number and spacing of doses, four different
starting designs are considered in the simulations (Table 1). For the first stage,
patients are allocated equally between the doses considered.
Design A Five equally spaced doses ξA = (0, 2, 4, 6, 8)
Design B Five unequally spaced doses (mostly low doses) ξB = (0, 1, 2, 4, 8)
Design C Five unequally spaced doses (mostly high doses) ξC = (0, 6, 7, 7.5, 8)
Design D Nine equally spaced doses ξD = (0, 1, 2, 3, 4, 5, 6, 7, 8)
Table 1: Starting designs
Designs A and B reflect what is most commonly seen in practice, in particular,
design B is an equal distribution on the log2 scale. Design C is more unusual but
can occur if the dose range considered is too narrow and the lowest dose is not
low enough. Design D is less likely to be seen in practice as it is unusual to see
so many dose levels utilized.
At the interim analysis it is assumed that 17 equally spaced doses can be
utilized ranging from 0 to 8 in 0.5 increments: x = (0, 0.5, 1, 1.5, 2, . . . , 7.5, 8).
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3.2 Dose-response profiles
A total of four different dose-response profiles were used to simulate the primary
endpoint, which are considered to span a range of dose-response profiles often
observed in practice (Figure 3). As in Bornkamp et al. (2007), for all models
the placebo effect was set to 0 and the maximum effect within the observed dose
range was set to −1.65 units.
Linear: η(x,θ) = −(1.65/8)x
Quadratic: η(x,θ) = −(1.65/3)x+ (1.65/36)x2
Emax: η(x,θ) = −1.81x/(0.79 + x)
Sigmoid Emax: η(x,θ) = −1.70x5/(45 + x5)
The residual error is assumed to be independently normally distributed with
mean 0 and variance 4.5.
Note that despite the fact that the linear and quadratic model are used here
as true simulation scenarios, we will always only use the sigmoid Emax model
to update the design and analyse the simulated studies. So for the linear and
quadratic scenarios we investigate the behaviour of the procedure under mis-
specification of the dose-response model.
3.3 Sample size and timing of interim analysis
Two total sample sizes are used in the simulations: 150 and 250 patients. These
sample sizes are consistent with those commonly used in neuropathic pain dose-
finding studies (Bornkamp et al., 2007). The timing of the interim analysis was
varied in order to consider the impact of sample size in the first stage. Seven
different timings for the interim analysis were considered for each total sample
size (Table 2).
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Figure 3: Dose-response profiles
Sample size in first stage N (1)
N = 150: 15 38 60 83 105 128 150
N = 250: 15 54 93 133 172 211 250
Table 2: First stage sample size
A fixed design is also included for comparison to the adaptive designs. This
corresponds to the scenario when the sample size for the first stage is 150 or
250 for N = 150 and N = 250 respectively. For the fixed designs, all study
participants are assigned to pre-specified doses according to the starting design
and there is no updating of the design. Two types of updating were considered
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at the interim analysis; ML and Bayesian updating. For each of the 448 scenarios
outlined above, 5, 000 trials were simulated.
3.4 Simulation metrics
To ensure comparability of the two approaches for design updating we used ML
estimation at study end to estimate the dose-response curve in both situations.
That means also in the situation where Bayesian updating was used at the in-
terim analysis, at study end ML was used to estimate the dose-response model
parameters. The parameter bounds for θ3, θ4 as discussed in Section 2.3.1 will be
used for fitting the dose-response model.
3.4.1 Efficiency of the second stage design
The relative efficiency of the second stage design is defined as
RelEff =
|M(ξ(2),θ)|
|M(ξ∗,θ)| (10)
This is the ratio of the determinant of the information matrix evaluated at the
second stage design ξ(2) to the determinant of the information matrix evaluated
at the locally optimal design ξ∗, assuming that the true parameter values θ are
known. The relative efficiency is bound between 0 and 1. The closer the relative
efficiency is to 1, the closer the second stage design is to truly optimal.
Whilst the true sigmoid Emax model parameter values are known for the
Emax and the sigmoid Emax model scenario, best fitting “pseudo-true” pa-
rameter values must be calculated for the linear and quadratic model scenar-
ios. This is achieved by using least-squares regression to fit the sigmoid Emax
model to the true mean function from the linear and quadratic dose-response
models at the doses x. The best fitting sigmoid Emax model parameters for the
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linear model were θ = (−0.0396,−4.305, 12, 1.349) and for the quadratic model
θ = (−0.06617,−1.661, 1.823, 1.948).
3.4.2 Mean absolute error
As a second metric we will investigate the mean absolute error (MAE) for esti-
mating the dose-response curve (as in Bornkamp et al. (2007)). This is defined
as
MAE =
1
q
q∑
i=1
|η(xi, θˆ)− ηtrue(xi)|, (11)
where θˆ is the ML estimate at study end, and ηtrue(x) the true dose-response
model function in this scenario. The mean absolute error is calculated for both
the adaptive (MAEadapt) and non-adaptive designs (MAEfixed). For the non-
adaptive design the timing of the ‘interim’ occurs after all N patients have been
allocated, i.e. there is only one stage.
The MAE ratio is defined as
RatioMAE =
MAEfixed
MAEadapt
(12)
and can be used to compare the adaptive design to the non-adaptive, with a ratio
greater than 1 suggesting that the adaptive design performs better.
4 Results
4.1 Efficiency of the second stage design
The distribution of efficiencies of the calculated second stage design are illustrated
in Figure 4. One can observe that in most of the situations the mean efficiency of
Bayesian updating outperforms the ML updating, in particular for early interim
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analyses, for the sigmoid Emax model scenario and the “bad” starting design C.
For all dose-response scenarios it can be seen that the efficiency curves for
the Bayesian designs only slightly increasing sometimes almost flat, while for
ML-based updating the dependency on the size of the first stage is much larger,
which might be due to the acknowledgment of parameter uncertainty.
Another interesting observation is that the variability of the efficiencies for the
calculated design are considerably smaller for Bayesian designs compared to the
designs calculated based on ML. So using a design criterion that acknowledges
uncertainty, results in less variable second stage designs.
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Figure 4: Mean (solid line) with 10% and 90% quantiles (dashed lines) of the
observed relative efficiencies of ML and Bayesian updating. N = 250
The results for N = 150 are similar and can be found in Appendix C. In
Table 3 one can observe the efficiency of the used starting designs, compared to
the locally optimal ones. One can see from the Table that, apart from design C, a
few of the designs have an efficiency of > 0.8, so that not too much is gained from
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the adaptive designs, when comparing the efficiencies obtained from the adaptive
designs in Figure 4. In other words, if the starting design already performs well,
then there is less efficiency to be gained by updating the design at an interim
analysis.
Linear Quadratic Emax Sig Emax
Design A 0.91 0.61 0.62 0.73
Design B 0.89 0.92 0.79 0.58
Design C 0.22 0.03 0.19 0.12
Design D 0.81 0.76 0.63 0.86
Table 3: Efficiencies of the different starting designs compared to the correspond-
ing local D optimal designs for the sigmoid Emax model
4.2 Mean Absolute Error
The ratio of the mean absolute error of the fixed versus the adaptive design is
illustrated for each starting design when the sample size N = 250, in Figure 5.
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Figure 5: Ratio of the MAE: N = 250
As can be seen in Figure 5, Bayesian updating seems to outperform ML updat-
ing of the design, also in this metric. This happens in particular for early interim
analyses. When the size of the first stage increases Bayesian and ML updating
become more similar. This is a quite general conclusion across all scenarios.
It can be seen that the benefit of adaption depends strongly on the starting
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design. For starting design C one gains in all scenarios, while in other situations
the gain is less apparent. For example, for starting design A one gains something
by adapting in the Emax scenario and not much for the sigmoid Emax scenario,
while for starting design B it is the other way round. This is also consistent with
the efficiencies of the starting design in Table 3, all scenarios where a benefit
of adaption could be observed in Figure 5 correspond to scenarios, where the
starting design has an efficiency of less than 0.7.
The MAE ratio plots corresponding to the smaller sample size of 150 can be
found in Appendix C. The findings for N = 150 are similar to those presented
above for N = 250.
5 Conclusions
From the simulation performed it seems that Bayesian updating of parameter
estimates at interim analysis can be used to account for parameter uncertainty.
Assigning functional uniform priors to the parameters has been shown to in-
crease the efficiency of the second stage design when compared to ML updating
methods, at least in the scenarios studied. The improvement was particularly
pronounced for early interim analyses. It would be reasonable to assume that if
accurate and valid informative priors could be derived for the parameters, then
the improvement may increase further.
An interesting side-result of the simulations is that the benefit of including an
interim analysis has not been shown to universally to improve the performance
of a dose-finding study. This result is consistent with other simulation studies
(Miller et al., 2007; Dragalin et al., 2010; Bornkamp et al., 2011; Jones et al.,
2011). Factors such as the signal to noise ratio at interim, or the efficiency of
the starting design (as discussed in Dette et al. (2013)) need to be taken into
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account. For the rather realistic scenarios discussed in this paper, not much
benefit could be expected, as the starting designs, with exception of design C, all
already performed relatively well. So most benefit is expected for strongly mis-
specified starting designs, such as design C. Practical experience suggests that
such a scenario, where the increasing part of the dose-response curve is missed
in the starting design, is actually not so rare. So in cases of great uncertainty on
the dose-response curve (at trial design stage) an adaptive design is a valuable
option to consider.
A potentially promising modification of the interim updating strategy, could
be “update-on-demand” adaptive designs. Here one would evaluate the efficiency
of the starting design at interim based on current information (i.e. the current
posterior distribution, or ML estimate). One would then only update the design,
if the estimated efficiency of the starting design is smaller than some threshold.
If the estimated efficiency of the starting design is larger than some threshold one
would continue with the starting design until study end.
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A K-means approximation of the full posterior
distribution
A.1 Justification of k-means approximation of posterior
distribution
Suppose one would like to approximate an integral
∫
g(θ)pi(θ)dθ, (13)
where pi(θ) is the posterior density, with θ ∈ Rd, and a posterior sample θ1, . . . ,θT
is available.
Suppose also that the function g is expensive to evaluate so that the plain
Monte Carlo estimate, 1
T
∑T
t=1 g(θt), is not feasible to evaluate, as T is large.
One approach is to use the k-means clustering algorithm to obtain cluster
centers a1, . . . ,ak ∈ Rd with k << T . This approach works by minimizing
k∑
i=1
∑
θt∈Ωi
||ai − θt||2, (14)
with respect to the cluster centers a1, . . . ,ak ∈ Rd, where Ωi is given by Ωi =
{θ ∈ Rd| ||θ − ai|| = min
i∈{1,...,k}
||θ − ai||}. That means that every point θ ∈ Rd
belongs to one set Ωi. The probability of the sets Ωi under pi: αi =
∫
Ωi
pi(θ)dθ
can be estimated by the proportion α̂i of samples within Ωi.
Using these considerations one can come up with a discrete approximation of
the posterior distribution of form p˜i(θ) =
∑k
i=1 α̂iδai(θ), where δa(θ) denotes the
function that is equal to 1 if θ = a and 0 otherwise.
Now the idea is to approximate the integral
∫
g(θ)pi(θ)dθ by the correspond-
ing integral with respect to p˜i, being given by
∑k
i=1 α̂ig(ai).
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Now the integration error is given by∣∣∣∣∣
∫
g(θ)pi(θ)dθ −
k∑
i=1
α̂ig(ai)
∣∣∣∣∣
=
∣∣∣∣∣
k∑
i=1
∫
Ωi
g(θ)pi(θ)dθ − αig(ai) + αig(ai)− α̂ig(ai)
∣∣∣∣∣
=
∣∣∣∣∣
k∑
i=1
∫
Ωi
(g(θ)− g(ai))pi(θ)dθ + αig(ai)− α̂ig(ai)
∣∣∣∣∣
≤
∣∣∣∣∣
k∑
i=1
∫
Ωi
(g(θ)− g(ai))pi(θ)dθ
∣∣∣∣∣+ |(αi − α̂i)g(ai)| (15)
The term on the right of Equation (15) will converge almost surely towards
zero when k-means is used to derive a1, . . . ,ak, see Pollard (1981). As the number
of samples T will be large in relation to k, this term will typically converge quite
quick towards 0.
The term on the left can be treated with arguments as in (Page`s, 1997, Propo-
sition 7). One can derive an upper bound as
k∑
i=1
∫
Ωi
|g(ai)− g(θ)|pi(θ)dθ ≤ L
k∑
i=1
∫
Ωi
||ai − θ||pi(θ)dθ (16)
which holds under the assumption that g is Lipschitz continuous with bound
L. Minimizing this upper bound with respect to a1, . . . ,ak will hence minimize
an upper bound of the integration error. In practice of course (16) cannot be
optimized directly as pi(θ) is not available in a closed form. Only a sample
θ1, . . . ,θT is available. The empirical version of the upper bound in (16) is
proportional to
k∑
i=1
∑
θt∈Ωi
||ai − θt||, (17)
which is very similar to the k-means objective function, see Equation (14). Graf
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and Luschgy (2002) consider the speed of convergence of the empirical version.
But again as T will typically rather large this will be less of an issue.
B Simulation scenario
The simulation scenario used to investigate the efficiency of the k-means approxi-
mation in terms of relative performance and running time, used as starting design
five unequally spaced doses, ξ = (0, 1, 2, 4, 8) (Design B) with balanced alloca-
tions. The sigmoid Emax dose-response model was used to simulate the response
data with
η(x,θ) =
−1.70x5
(45 + x5)
(18)
and an independent normally distributed residual error term with mean 0 and
variance 4.5.
C Simulation results for N = 150
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Figure 6: Mean (solid line) with 10% and 90% quantiles (dashed lines) of the
observed relative efficiencies of ML and Bayesian updating. N = 250
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